A non-profit member organization

Algenis

September 21, 2018

Algenis specializes in the production, formulation, and clinical development of bioactive molecules produced by marine microalgae with medical application as muscle relaxant and analgesic, as well as for the treatment of neurological diseases.

Sign up for LAVCA’s bi-weekly Latin American Private Capital Update and the LatAm Venture Bulletin, produced specifically for venture investors, entrepreneurs, and technology startups in the early stage ecosystem.

Email Address *

First Name *

Last Name *

Company *

Country

Which LAVCA Newsletter would you like to receive?

Private Capital Update
LatAm Venture Bulletin

Tweets

"According to LAVCA Data, VC investment into Latin American fintech totaled USD1.2b in the first quarter of 2022."… https://t.co/oikd3BXiCU

24-Jun-2022

Reply Retweet Favorite
Felicitaciones a la Directora Ejecutiva de LAVCA @lavca_org Ángela María Tafur @naitafur quien se ha incorporado al… https://t.co/qjHgnmFPS3

14-Jun-2022

Reply Retweet Favorite
LAVCA's Director of Venture Capital @crdelavega_ shares insights with @TechCrunch's @bayareawriter on the latest d… https://t.co/krypDTI5NE

14-Jun-2022

Reply Retweet Favorite
Congratulations to LAVCA's Executive Director @naitafur who has joined the Board of Directors of @GRUPOSURA. https://t.co/47bv5fyVhT

13-Jun-2022

Reply Retweet Favorite
In 2018, @_AquaCapital invested in agricultural biologicals platform @Biotropbr. In 3 years, the company has reduce… https://t.co/PDu5zkchTs

13-Jun-2022

Reply Retweet Favorite

Algenis

VC Partner Events

Tweets

Submit VC News

VC Industry News